West Pharmaceutical Services Inc (NYSE: WST)

Sector: Healthcare Industry: Medical Instruments & Supplies CIK: 0000105770
Market Cap 15.98 Bn
P/B 28.26
P/E 228.35
P/S 15.87
ROIC (Qtr) 13.65
Div Yield % 0.21
Rev 1y % (Qtr) 7.51
Total Debt (Qtr) 321.10 Mn
Debt/Equity (Qtr) 0.10
Add ratio to table...

About

West Pharmaceutical Services Inc. (WST) is a leading global manufacturer specializing in the production of advanced, high-quality, and integrated containment and delivery systems for injectable drugs and healthcare products. The company operates in two primary business segments: Proprietary Products and Contract-Manufactured Products. These segments offer a variety of solutions, including primary packaging, containment systems, reconstitution and transfer systems, drug delivery systems, contract manufacturing, analytical lab services, and integrated...

Read more

Investment thesis

Bull case

  • Strong operating cash flow of 754.80M provides robust 2.35x coverage of total debt 321.10M, indicating excellent debt servicing capability and financial flexibility.
  • Healthy cash reserves of 791.30M provide 34.86x coverage of short-term debt 22.70M, demonstrating strong liquidity position and minimal refinancing risk.
  • Operating cash flow of 754.80M provides exceptional 1509.60x coverage of interest expenses 500000, showing strong debt service capability.
  • Operating cash flow of 754.80M provides strong 31.71x coverage of stock compensation 23.80M, indicating sustainable incentive practices.
  • Strong tangible asset base of 4.15B provides 12.93x coverage of total debt 321.10M, indicating robust asset backing and low credit risk.

Bear case

  • Operating cash flow of 754.80M barely covers its investment activities of (285.90M), with a coverage ratio of -2.64, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Operating cash flow of 754.80M provides thin coverage of dividend payments of (61.20M) with a -12.33 ratio, suggesting potential dividend sustainability issues if operational performance deteriorates.
  • Investment activities of (285.90M) provide weak support for R&D spending of 74.30M, which is -3.85x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Free cash flow of 468.90M represents just -426.27x of debt issuance (1.10M), suggesting concerning reliance on leverage rather than internal cash generation for growth.
  • Operating cash flow of 754.80M is outpaced by equity issuance of (125.50M) (-6.01 ratio), indicating concerning reliance on equity markets for funding operations.

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Instruments & Supplies
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ISRG Intuitive Surgical Inc 176.13 Bn 61.67 17.50 0.00 Bn
2 BDX Becton Dickinson & Co 50.84 Bn 28.94 2.32 19.54 Bn
3 ALC Alcon Inc 39.87 Bn 38.08 3.91 5.24 Bn
4 RMD Resmed Inc 37.63 Bn 36.86 8.03 0.85 Bn
5 HOLX Hologic Inc 16.89 Bn 31.05 4.09 2.52 Bn
6 COO Cooper Companies, Inc. 16.34 Bn 43.59 3.99 2.51 Bn
7 WST West Pharmaceutical Services Inc 15.98 Bn 228.35 15.87 0.32 Bn
8 ALGN Align Technology Inc 13.70 Bn 36.21 3.44 0.09 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 3.82 2.69
EV to Cash from Ops. EV/CFO 126.18 33.85
EV to Debt EV to Debt 50.73 26.88
EV to EBIT EV/EBIT 158.31 21.42
EV to EBITDA EV/EBITDA 97.90 13.45
EV to Free Cash Flow [EV/FCF] EV/FCF 7,082.70 108.54
EV to Market Cap EV to Market Cap 1.02 -4.25
EV to Revenue EV/Rev 16.18 291.65
Price to Book Value [P/B] P/B 28.26 6.13
Price to Earnings [P/E] P/E 228.35 168.84
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Div Coverage (Qtr) 8.07 -1.12
Dividend Payout Ratio % Div Payout % (Qtr) 12.40 2.62
Dividend per Basic Share Div per Share (Qtr) 0.86 0.25
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 13.26 7.48
Interest Coverage Int. cover (Qtr) 1,231.60 11.77
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) 24.16 -62.99
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 63.29 419.59
Dividend Growth (1y) % Div 1y % (Qtr) 4.88 -1.67
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -0.21 -57.55
EBITDA Growth (1y) % EBITDA 1y % (Qtr) 4.27 -107.89
EBIT Growth (1y) % EBIT 1y % (Qtr) 2.09 -37.41
EBT Growth (1y) % EBT 1y % (Qtr) 2.52 -40.02
EPS Growth (1y) % EPS 1y % (Qtr) 1.19 -9.45
FCF Growth (1y) % FCF 1y % (Qtr) 69.65 57.56
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 10.57 66.70
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.72 0.54
Cash Payout Ratio Cash Payout (Qtr) 0.06 0.03
Cash Ratio Cash Ratio (Qtr) 1.21 2.52
Current Ratio Curr Ratio (Qtr) 3.02 7.80
Debt to Equity Ratio Debt/Equity (Qtr) 0.10 0.55
Interest Cover Ratio Int Coverage (Qtr) 1,231.60 11.77
Times Interest Earned Times Interest Earned (Qtr) 1,231.60 11.77
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) 25.60 -2,368.82
EBIT Margin % EBIT Margin % (Qtr) 20.03 -2,472.83
EBT Margin % EBT Margin % (Qtr) 20.02 -2,442.75
Gross Margin % Gross Margin % (Qtr) 35.90 29.78
Net Profit Margin % Net Margin % (Qtr) 16.10 -2,438.72